Updates on HER2-Directed ADCs Across Solid Tumors - Episode 11

Managing ILD and Pneumonitis Risk From ADCs

, , , ,

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

EP. 1: Assessing HER2 Status Across Tumor Types
EP. 2: ADCs Targeting HER2+ Breast Cancer
EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
EP. 5: ADCs Targeting GI Cancers
EP. 6: ADCs Targeting HER2+ Lung Cancer
EP. 7: Impact of ADCs on Brain Metastases
EP. 8: ADCs Targeting HER2+ GU Cancers
EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
Now Viewing
EP. 11: Managing ILD and Pneumonitis Risk From ADCs
EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
EP. 13: Managing Hematologic AEs Associated with ADC Treatments
EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
EP. 15: ADC Sequencing
EP. 16: Emerging ADCs in Development
EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
EP. 18: The Future for HER2-Directed ADCs
EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

  1. What are the most common toxicities associated with ADCs? Which are most concerning for physicians? For patients?
  2. What toxicities are of greatest concern for patients withgynecologic, GI, Lung ,and GU cancers?